112P Patients’ knowledge about ductal carcinoma in situ
Ellen G. Engelhardt(The Netherlands Cancer Institute), Eveline M. A. Bleiker(Cancer Clinic), E. Verschuur-van der Voort(Borstkankervereniging Nederland), C. Sondermeijer(The Netherlands Cancer Institute), Miranda A. Gerritsma(The Netherlands Cancer Institute), Frederieke van Duijnhoven(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Marja van Oirsouw(Borstkankervereniging Nederland), Renée Schmitz(The Netherlands Cancer Institute), Valesca P. Retèl(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center)
Cited by 0
Related Papers
(untitled)
|Edinburgh Research Explorer|0|353
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
|Journal of Clinical Oncology|2011|306
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
|The Lancet Oncology|2007|278
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
|Breast Cancer Research and Treatment|2009|256
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
|British Journal of Cancer|2013|241